What is the purpose of this trial?
Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.
Actelion Clinical Operations, Inc.
Start Date: 06/29/2015
End Date: 10/01/2018
Last Updated: 02/22/2018
Study HIC#: 1503015421REG